Clinical Pharmacology of Myocardial Energetic Efficiency–Targeted Pharmacotherapy

Abstract

The optimization of myocardial energetic efficiency represents a promising frontier in the pharmacological management of cardiac diseases, particularly heart failure. Targeting the metabolic and energetic pathways of cardiomyocytes has evolved from theoretical interest to the development and clinical application of novel pharmacotherapies. This review examines the clinical pharmacology, evidence base, and practical implications of agents developed or repurposed to enhance myocardial energetic efficiency. We discuss the underlying pathophysiological rationale, current and emerging therapeutic classes, key clinical trials, and guideline recommendations for energy-targeting strategies in routine practice.

Introduction

Heart failure and ischemic heart disease are characterized not only by hemodynamic compromise but also by impaired myocardial energetics. The heart, with its high metabolic demand, is particularly sensitive to disruptions in adenosine triphosphate (ATP) generation and substrate utilization. Traditional therapies focus on neurohormonal modulation and afterload reduction. However, there is growing recognition of the therapeutic potential in directly enhancing myocardial energy metabolism. Pharmacological interventions designed to improve energetic efficiency aim to optimize substrate selection, mitochondrial function, and ATP production, ultimately supporting contractile performance and reducing adverse remodeling.

Epidemiology / Disease Burden

Cardiovascular diseases remain the leading cause of mortality globally, with heart failure affecting over 64 million individuals worldwide. The prevalence of energy metabolism disturbances is particularly high in patients with chronic heart failure, cardiomyopathies, and ischemic syndromes. Observational studies have identified that up to 70% of heart failure patients exhibit metabolic remodeling, underscoring the clinical importance of myocardial energetic inefficiency. The associated morbidity, hospitalizations, and healthcare costs highlight the urgent need for novel pharmacological approaches that go beyond symptomatic relief and address underlying metabolic dysfunction.

Pathophysiology

In healthy myocardium, ATP is primarily generated via oxidative phosphorylation, with fatty acids and glucose serving as principal substrates. Under pathological stress such as ischemia, pressure overload, or neurohormonal activation there is a shift toward less efficient energy production pathways, increased reliance on glycolysis, and impaired mitochondrial oxidative capacity. This leads to decreased ATP availability, accumulation of metabolic intermediates, and increased production of reactive oxygen species (ROS). These changes contribute to contractile dysfunction, adverse remodeling, and progression of heart failure. The conceptual basis for energetic efficiency–targeted pharmacotherapy lies in restoring balanced substrate utilization, optimizing mitochondrial function, and enhancing ATP synthesis.

Risk Factors

Several risk factors predispose individuals to myocardial energetic inefficiency, including chronic ischemia, diabetes mellitus, obesity, hypertension, genetic predispositions, and persistent neurohormonal stimulation. Insulin resistance and hyperlipidemia, in particular, alter substrate availability and promote maladaptive metabolic remodeling. Additionally, advancing age and comorbid conditions such as chronic kidney disease can exacerbate energetic deficits through both direct mitochondrial effects and systemic metabolic disturbances.

Clinical Features

Clinically, impaired myocardial energetics manifest as progressive exercise intolerance, fatigue, dyspnea, and reduced contractile reserve. In advanced stages, patients may exhibit signs of low cardiac output, refractory heart failure, and arrhythmias. Biomarkers such as elevated B-type natriuretic peptide (BNP) and troponin, as well as imaging findings of impaired systolic and diastolic function, often correlate with underlying energetic deficits. Importantly, these clinical features may persist despite optimization of conventional heart failure therapies, suggesting the need for targeted metabolic interventions.

Diagnosis

Assessment of myocardial energetic status is primarily indirect, relying on a combination of clinical, biochemical, and imaging parameters. Advanced modalities such as phosphorus-31 magnetic resonance spectroscopy (31P-MRS) allow for in vivo quantification of cardiac phosphocreatine-to-ATP ratios, providing insight into myocardial energy reserves. Echocardiography and cardiac MRI can identify functional consequences of energetic inefficiency, including reduced ejection fraction and impaired myocardial strain. Laboratory evaluation may reveal elevated lactate, abnormal lipid profiles, and evidence of systemic metabolic dysfunction. Genetic testing may be considered in patients with suspected inherited cardiomyopathies affecting mitochondrial function.

Treatment & Management

Conventional heart failure management including beta-blockers, renin-angiotensin-aldosterone system (RAAS) inhibitors, and diuretics primarily addresses hemodynamic and neurohormonal pathways. However, specific pharmacotherapies targeting myocardial energetics are gaining clinical prominence. Trimetazidine and ranolazine, both partial fatty acid oxidation inhibitors, shift substrate utilization toward glucose oxidation, improving cardiac efficiency and function. Perhexiline, a carnitine palmitoyltransferase-1 (CPT-1) inhibitor, similarly enhances glucose metabolism but requires monitoring for hepatotoxicity and peripheral neuropathy. Other agents, such as SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin), originally developed for diabetes, have demonstrated myocardial energy benefits, possibly due to increased ketone substrate utilization and improved mitochondrial efficiency. The use of these agents requires careful patient selection, monitoring for adverse effects, and integration with standard-of-care therapies.

Recent Advances / Emerging Therapies

Recent research has focused on novel pharmacological strategies to further enhance myocardial energetic efficiency. Mitochondria-targeted antioxidants, such as elamipretide, aim to reduce ROS-mediated damage and preserve ATP synthesis. Agents modulating pyruvate dehydrogenase activity, such as dichloroacetate, are being investigated for their ability to promote glucose oxidation. Additionally, ongoing studies are evaluating the clinical impact of direct ketone supplementation, which may offer a more efficient fuel source for the failing myocardium. Gene and cell therapies targeting mitochondrial biogenesis and function represent an exciting, albeit experimental, avenue for future intervention. The integration of omics technologies and personalized medicine approaches is anticipated to refine patient selection and therapeutic targeting.

Guideline Recommendations

International guidelines increasingly acknowledge the importance of myocardial energetic modulation in heart failure management. The 2021 ESC guidelines recommend consideration of metabolic modulators such as trimetazidine in selected patients with angina or heart failure refractory to conventional therapy. SGLT2 inhibitors have been incorporated into guideline-directed medical therapy for heart failure with reduced ejection fraction, supported by robust evidence of improved clinical outcomes and potential energetic benefits. However, the routine use of other metabolic agents remains limited by heterogeneity in clinical trial data, variable regulatory approval, and concerns regarding safety profiles. Ongoing large-scale trials are expected to clarify the long-term benefits and optimal patient populations for these therapies.

Conclusion

Advances in the clinical pharmacology of myocardial energetic efficiency–targeted pharmacotherapy offer new hope for patients with heart failure and related cardiac disorders. By addressing the fundamental metabolic derangements underlying cardiac dysfunction, these agents complement traditional neurohormonal and hemodynamic therapies. Current evidence supports the integration of metabolic modulators, particularly SGLT2 inhibitors, into contemporary practice, while emerging therapies hold promise for further improving outcomes. Continued research, careful patient selection, and adherence to evolving guideline recommendations will be essential to fully realize the potential of these innovative pharmacological strategies.